Riluzole Oral Suspension (Tiglutik) Shortage: Manufacturing Issues Impact Availability

What’s in Shortage

Riluzole Oral Suspension, a medication categorized for use in neurology, is currently listed in the FDA drug shortage database. This shortage affects specific presentations of the brand-name medications TEGLUTIK and TIGLUTIK. While some concentrations remain available, the 50 mg/10 mL presentation of Tiglutik is currently unavailable.

Which Manufacturers Are Affected

EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)

The following presentations are currently Available:

• Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)
• Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)
• Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)

The following presentation is currently Unavailable:

• Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-2)

Patients or providers with questions can contact the manufacturer directly at 610-937-6172.

Why There’s a Shortage

According to the manufacturer, the shortage of the Tiglutik 50 mg/10 mL presentation is due to a product manufacturing interruption related to viscosity testing. A date for the next product release is not available at this time.

What Patients Should Do

If you are currently prescribed Riluzole Oral Suspension, please consider the following steps:

• Consult your healthcare provider: Discuss the current availability and how it may impact your specific treatment plan.
• Speak with your pharmacist: Inquire about the stock status of the available 5 mg/1 mL presentations.
• Contact the manufacturer: You may call EDW Pharma, Inc. at 610-937-6172 for updates regarding supply timelines.

Disclaimer: Patients should always consult their healthcare provider or pharmacist regarding medication changes or treatment concerns.

Source

Information provided by the FDA Drug Shortage Database.
Initial Posting Date: 01/26/2024
Last Updated: 02/02/2026